Top

Osteoporosis International

Published in:

01-02-2014 | Original Article

Risk of fracture in patients with muscular dystrophies

Authors: S. Pouwels, A. de Boer, H. G. M. Leufkens, W. E. J. Weber, C. Cooper, H. A. W. van Onzenoort, F. de Vries

Published in: Osteoporosis International | Issue 2/2014

Abstract

Summary

The aim of the study was to determine fracture risk in incident muscular dystrophy (MD) patients. Patients with MD are at a 1.4-fold increased risk of fracture as compared with population-based control patients. Risk further increased among elderly and female patients and among patients exposed to oral glucocorticoids.

Introduction

Muscular dystrophies (MDs) are inherited diseases causing muscle weakness and thereby increase the risk of falling and detrimental effects on bone. Both are recognised risk factors for fracture. Therefore, the aim of this study was to determine the hazard ratio of fracture in patients with MD.

Methods

We conducted a retrospective cohort study using the UK General Practice Research Database (1987–2012). Each patient with MD was matched by year of birth, sex and practice to up to six patients without a history of MD. Outcome measure was all fractures.

Results

As compared with control patients, risk of any fracture was statistically significantly increased in MD patients (adjusted hazard ratio [AHR], 1.40; 95 % confidence interval [CI], 1.14–1.71). An increased risk of fracture was observed among MD patients with female gender (AHR, 1.78; 95 % CI, 1.33–2.40) and an increasing age as compared with control patients. Stratification to Duchenne MD showed no association with fracture, whereas risk of fracture was increased twofold among patients with myotonic dystrophy (AHR, 2.34; 95 % CI, 1.56–3.51). MD patients had an almost tripled risk of fracture when they used oral glucocorticoids in the previous 6 months as compared to non-users with MD.

Conclusion

Patients with MD are at a 1.4-fold increased risk of fracture as compared with population-based control patients. Especially in older age groups and female gender, the fracture risk of MD versus non-MD patients is increased, whereas exposure to glucocorticoids further increased fracture risk among MD patients.

Emery AE (2002) The muscular dystrophies. Lancet 359(9307):687–695PubMedCrossRef

Udd B, Krahe R (2012) The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 11(10):891–905PubMedCrossRef

King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, Hoyle C, Mendell JR, Kissel JT (2007) Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 68(19):1607–1613PubMedCrossRef

McDonald DG et al (2002) Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neurol 44(10):695–698PubMedCrossRef

Bothwell JE et al (2003) Vertebral fractures in boys with Duchenne muscular dystrophy. Clin Pediatr (Phila) 42(4):353–356CrossRef

Parker AE, Robb SA, Chambers J, Davidson AC, Evans K, O’Dowd J, Williams AJ, Howard RS (2005) Analysis of an adult Duchenne muscular dystrophy population. QJM 98(10):729–736PubMedCrossRef

Vestergaard P, Glerup H, Steffensen BF, Rejnmark L, Rahbek J, Moseklide L (2001) Fracture risk in patients with muscular dystrophy and spinal muscular atrophy. J Rehabil Med 33(4):150–155PubMedCrossRef

Horlings CG, Küng UM, van Engelen BG, Voermans NC, Hengstman GJ, van der Kooi AJ, Bloem BR, Allum JH (2009) Balance control in patients with distal versus proximal muscle weakness. Neuroscience 164(4):1876–1886PubMedCrossRef

Horlings CG, Munneke M, Bickerstaffe A, Laverman L, Allum JH, Padberg GW, Bloem BR, van Engelen BG (2009) Epidemiology and pathophysiology of falls in facioscapulohumeral disease. J Neurol Neurosurg Psychiatry 80(12):1357–1363PubMedCrossRef

10.

Moxley RT 3rd, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, Baumbach L, McDonald C, Sussman M, Wade C, Quality Standards Subcommittee of the American Academy of Neurology, Practice Committee of the Child Neurology Society (2005) Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 64(1):13–20PubMedCrossRef

11.

De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56(1):208–214PubMedCrossRef

12.

Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15(6):993–1000PubMedCrossRef

13.

Carson AJ, Postma K, Stone J, Warlow C, Sharpe M (2003) The outcome of depressive disorders in neurology patients: a prospective cohort study. J Neurol Neurosurg Psychiatry 74(7):893–896PubMedCrossRef

14.

Kalkman JS, Schillings ML, Zwarts MJ, van Engelen BG, Bleijenberg G (2007) Psychiatric disorders appear equally in patients with myotonic dystrophy, facioscapulohumeral dystrophy, and hereditary motor and sensory neuropathy type I. Acta Neurol Scand 115(4):265–270PubMedCrossRef

15.

van den Brand MW, Samson MM, Pouwels S, van Staa TP, Thio B, Cooper C, Leufkens HG, Egberts AC, Verhaar HJ, de Vries F (2009) Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int 20(10):1705–1713PubMedCentralPubMedCrossRef

16.

Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F (2009) Antipsychotic use and the risk of hip/femur fracture: a population-based case–control study. Osteoporos Int 20(9):1499–1506PubMedCentralPubMedCrossRef

17.

Vestergaard P, Prieto-Alhambra D, Javaid MK, Cooper C (2013) Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose. Osteoporos Int 24(2):671–680PubMedCentralPubMedCrossRef

18.

Walley T, Mantgani A (1997) The UK General Practice Research Database. Lancet 350:1097–1099PubMedCrossRef

19.

Van Staa TP, Abenhaim L (1994) The quality of information recorded on a UK database of primary care records: a study of hospitalization due to hypoglycemia and other conditions. Pharmacoepidemiol Drug Saf 3:15–21CrossRef

20.

Van Staa TP, Abenhaim L, Cooper C, Begaud B, Zhang B, Leufkens HG (2000) The use of a large pharmaco-epidemiological database to study exposure to oral glucocorticoids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 9:359–366PubMedCrossRef

21.

Hoogerwaard EM, Bakker E, Ippel PF, Oosterwijk JC, Majoor-Krakauer DF, Leschot NJ, Van Essen AJ, Brunner HG, van der Wouw PA, Wilde AA, de Visser M (1999) Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet 353(9170):2116–2119PubMedCrossRef

22.

ICD-10 Classification. World Health Organization. http://www.who.int/classifications/icd/en/. Accessed 28 Feb 2013

23.

Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2:90–95PubMedCrossRef

24.

Bione S, Maestrini E, Rivella S et al (1994) Identification of a novel X-linked gene responsible for Emery–Dreifuss muscular dystrophy. Nat Genet 8:323–327PubMedCrossRef

25.

Rahbek J, Werge B, Madsen A, Marquardt J, Steffensen BF, Jeppesen J (2005) Adult life with Duchenne muscular dystrophy: observations among an emerging and unforeseen patient population. Pediatr Rehabil 8(1):17–28PubMed

26.

Ceroni D, Martin X, Delhumeau C, Rizzoli R, Kaelin A, Farpour-Lambert N (2012) Effects of cast-mediated immobilization on bone mineral mass at various sites in adolescents with lower-extremity fracture. J Bone Joint Surg Am 94(3):208–216PubMedCrossRef

27.

Larson CM, Henderson RC (2000) Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop 20(1):71–74PubMed

28.

Sackley C, Disler PB, Turner-Stokes L, Wade DT (2007) Rehabilitation interventions for foot drop in neuromuscular disease. Cochrane Database Syst Rev (2):CD003908

29.

Aprile I, Padua L, Iosa M, Gilardi A, Bordieri C, Frusciante R, Russo G, Erra C, De Santis F, Ricci E (2012) Balance and walking in facioscapulohumeral muscular dystrophy: multiperspective assessment. Eur J Phys Rehabil Med 48(3):393–402PubMed

30.

Estrada K et al (2012) Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 44(5):491–501PubMedCentralPubMedCrossRef

Title: Risk of fracture in patients with muscular dystrophies
Authors: S. Pouwels
A. de Boer
H. G. M. Leufkens
W. E. J. Weber
C. Cooper
H. A. W. van Onzenoort
F. de Vries
Publication date: 01-02-2014
Publisher: Springer London
Published in: Osteoporosis International / Issue 2/2014
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-013-2442-2

At a glance: The STEP trials

Springer Medicine

Risk of fracture in patients with muscular dystrophies

Abstract

Summary

Introduction

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2014

Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass

Impact of nutrition on muscle mass, strength, and performance in older adults: response to Scott and Jones

The associations between QCT-based vertebral bone measurements and prevalent vertebral fractures depend on the spinal locations of both bone measurement and fracture

Efficacy of the dynamic radiographs for diagnosing acute osteoporotic vertebral fractures

Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?

The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers